Login to Your Account



Trius, Optimer Acquisitions Bring Dificid, MRSA Candidate

Cubist Gains Antibiotic Power Products in $1.6B Buying Spree

By Catherine Shaffer
Staff Writer

Tuesday, July 30, 2013

With the acquisition of Trius Therapeutics Inc. and Optimer Pharmaceuticals Inc. after the market closed Tuesday for a total of more than $1.6 billion, Cubist Pharmaceuticals Inc. has made a play to position itself as an antibiotic powerhouse in the biotech field.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription